Identification of Novel AXL Kinase Inhibitors Using Ligand-Based Pharmacophore Screening and Molecular Dynamics Simulations

被引:2
作者
Nagamalla, Lavanya [1 ,2 ]
Kumar, J. V. Shanmukha [1 ]
Shaik, Mohammed Rafi [3 ]
Sanjay, Chintakindi [4 ]
Alsamhan, Ali M. [4 ]
Kasim, Mohsin Ahmed [4 ]
Alwarthan, Abdulrahman [3 ]
机构
[1] Koneru Lakshmaiah Educ Fdn, Dept Chem Engn, Coll Engn, Vaddeswaram 522302, Andhra Pradesh, India
[2] Hyderabad Inst Technol & Management, Hyderabad 501401, Telangana, India
[3] King Saud Univ, Dept Chem, Coll Sci, POB 2455, Riyadh 11451, Saudi Arabia
[4] King Saud Univ, Dept Ind Engn, Coll Engn, POB 800, Riyadh 11451, Saudi Arabia
关键词
AXL kinase; pharmacophore model; virtual screening; cancer therapy; PubChem; molecular dynamics simulations; CONFORMATIONAL-ANALYSIS; CANCER; BREAST; MET; EXPLORATION; METASTASIS; SURVIVAL; PROTEIN; POTENT; TOOL;
D O I
10.3390/cryst12081158
中图分类号
O7 [晶体学];
学科分类号
0702 ; 070205 ; 0703 ; 080501 ;
摘要
AXL kinase is a promising target in novel drug discovery for cancer. A ligand-based pharmacophore model was generated with the Pharmit web server. Its inbuilt PubChem molecule database was screened and led to 408 candidate molecules. Docking of the AXL kinase active sites with the identified list of candidate molecules was carried out with Autodock Vina docking software. This resulted in four compounds selected for further investigation. Molecular dynamics simulation of two ligands (PubChem-122421875 and PubChem-78160848) showed considerable binding with AXL kinase. From the MM-PBSA binding free energies investigation, the PubChem-122421875 (G = -179.3 kJ/mol) and PubChem-78160848 (G = -208.3 kJ/mol) ligands had favorable protein-ligand complex stability and binding free energy. Hence, PubChem-122421875 and PubChem-78160848 molecules identified in this work could be a potent starting point for developing novel AXL kinase inhibitor molecules.
引用
收藏
页数:13
相关论文
共 45 条
  • [1] Arends J, 2010, ANTICANCER RES, V30, P1863
  • [2] Canonical sampling through velocity rescaling
    Bussi, Giovanni
    Donadio, Davide
    Parrinello, Michele
    [J]. JOURNAL OF CHEMICAL PHYSICS, 2007, 126 (01)
  • [3] The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase
    Gajiwala, Ketan S.
    Grodsky, Neil
    Bolanos, Ben
    Feng, Junli
    Ferre, RoseAnn
    Timofeevski, Sergei
    Xu, Meirong
    Murray, Brion W.
    Johnson, Ted W.
    Stewart, Al
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2017, 292 (38) : 15705 - 15716
  • [4] Molecular property diagnostic suite for diabetes mellitus (MPDSDM): An integrated web portal for drug discovery and drug repurposing
    Gaur, Anamika Singh
    Nagamani, Selvaraman
    Tanneeru, Karunakar
    Druzhilovskiy, Dmitry
    Rudik, Anastassia
    Poroikov, Vladimir
    Sastry, G. Narahari
    [J]. JOURNAL OF BIOMEDICAL INFORMATICS, 2018, 85 : 114 - 125
  • [5] Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival
    Gjerdrum, Christine
    Tiron, Crina
    Hoiby, Torill
    Stefansson, Ingunn
    Haugen, Hallvard
    Sandal, Tone
    Collett, Karin
    Li, Shan
    McCormack, Emmet
    Gjertsen, Bjorn Tore
    Micklem, David R.
    Akslen, Lars A.
    Glackin, Carlotta
    Lorens, James B.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (03) : 1124 - 1129
  • [6] Gas6 and the Receptor Tyrosine Kinase Axl in Clear Cell Renal Cell Carcinoma
    Gustafsson, Anna
    Bostrom, Anna-Karin
    Ljungberg, Borje
    Axelson, Hakan
    Dahlback, Bjorn
    [J]. PLOS ONE, 2009, 4 (10):
  • [7] Differential Expression of Axl and Gas6 in Renal Cell Carcinoma Reflecting Tumor Advancement and Survival
    Gustafsson, Anna
    Martuszewska, Danuta
    Johansson, Martin
    Ekman, Carl
    Hafizi, Sassan
    Ljungberg, Borje
    Dahlback, Bjorn
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (14) : 4742 - 4749
  • [8] Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer
    Hart, Christopher D.
    De Boer, Richard H.
    [J]. ONCOTARGETS AND THERAPY, 2013, 6 : 1 - 7
  • [9] Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO
  • [10] 2-H